Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani.
[en] Fusarium spp. have emerged as important causes of invasive fungal infections in immunocompromised patients. Rabbit pulmonary alveolar macrophages (PAMs) exhibited fungicidal activity against conidia of Fusarium solani and achieved a time-dependent increase in killing. Neither deoxycholate amphotericin B (DAMB) nor amphotericin B lipid complex (ABLC) exerted a suppressive effect on PAMs by decreasing their conidiocidal activity against F. solani. On the contrary, at a concentration of 0.125 microg ml(-1), ABLC and, to a lesser degree, DAMB additively augmented the fungicidal activity of pulmonary alveolar macrophages against conidia of Fusarium solani.
Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani.
Boutati EI Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997 90 999 1008.
Krcmery VJ Jesenska Z Spanik S et al. Fungaemia due to Fusarium spp. in cancer patients. J Hosp Infect 1997 36 223 8.
Reuben A Anaissie E Nelson PE et al. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother 1989 33 1647 9.
Anaissie EJ Hachem R Legrand C Legenne P Nelson P Bodey GP. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis 1992 165 1155 7.
Sekhon AS Padhye AA Garg AK Ahmad H Moledina N. In vitro sensitivity of medically significant Fusarium species to various antimycotics. Chemotherapy 1994 40 239 44.
Anaissie EJ Kuchar RT Rex JH et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001 33 1871 8.
Roilides E Lyman CA Filioti J et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2002 46 1974 6.
Espinel-Ingroff A Bartlett M Bowden R et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997 35 139 43.
Winn RM Gil-Lamaignere C Maloukou A Roilides E. Interactions of human phagocytes with moulds Fusarium spp. and Verticillium nigrescens possessing different pathogenicity. Med Mycol 2003 41 503 9.
Levitz S Selsted ME Ganz T Lehrer RI Diamond RD. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis 1986 154 483 9.
Schaffner A Douglas H Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982 69 617 31.
Waldorf A. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 1989 47 243 71.
Philippe B Ibrahim-Granet O Prevost MC et al. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect Immun 2003 71 3034 42.
Jahn B Rampp A Dick C Jahn A Palmer M Bhakdi S. Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level. Antimicrob Agents Chemother 1998 42 2569 75.
Roilides E Walsh TJ Rubin M Venzon D Pizzo AP. Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrob Agents Chemother 1990 34 196 201.
Sullivan GW Carper HT Mandell GL. Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro. Antimicrob Agents Chemother 1992 36 408 16.
Yasui K Masuda M Matusoka T et al. Miconazole and amphotericin B alter polymorphonuclear leukocyte functions and membrane fluidity in similar fashions. Antimicrob Agents Chemother 1988 32 1864 8.
Sullivan GW Carper HT Mandell GL. Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone). Antimicrob Agents Chemother 1992 36 39 45.
Supapidhayakul SR Kizlaitis LR Andersen BR. Stimulation of human and canine neutrophil metabolism by amphotericin B. Antimicrob Agents Chemother 1981 19 284 9.
Vora S Chauhan S Brummer E Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998 42 2299 303.
Chiller T Farrokhshad K Brummer E Stevens DA. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001 39 99 103.
Gil-Lamaignere C Roilides E Maloukou A Georgopoulou I Petrikkos G Walsh TJ. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002 50 1027 30.
Gil-Lamaignere C Roilides E Mosquera J Maloukou A Walsh TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002 46 2234 7.
Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994 14 Suppl 5 S3 S7.
Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microb Physiol 1986 27 1 72.
Groll AH Lyman CA Petraitiene R et al. Differential intrapulmonary disposition of voriconazole and liposomal amphotericin B in non-infected rabbits. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL American Society of Microbiology 2003 474.
Perkins WR Minchey SR Boni LT et al. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992 1107 271 82.
Yamaguchi H Abe S Tokuda Y. Immunomodulating activity of antifungal drugs. Ann NY Acad Sci 1993 685 447 57.
Rogers PD Jenkins JK Chapman SW Ndebele K Chapman BA Cleary JD. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis 1998 178 1726 33.
Roilides E Dimitriadou-Georgiadou A Sein T Kadiltzoglou I Walsh TJ. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998 66 5999 6003.
Wilson E Thorson L Speert DP. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother 1991 35 796 800.
Wolf JE Massof SE. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect Immun 1990 58 1296 300.
